Kevin Miller, DO
Family Medicine · Sisters, ORNPI 1457321333
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (33.8%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Eli Lilly at 26.8% of the total. 2025 is the largest year on record at $22,758, more than ten times the $1,289 reported in 2019. Among family medicine clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 263 payments — averaging $148.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$10K
- Lilly USA, LLC$7K
- Mannkind Corporation$7K
- Corcept Therapeutics$4K
- Abbott$2K
- Idorsia Pharmaceuticals US Inc$2K
- plus $8K from 33 others
What the payments were for
- Consulting fees$13,21934%
- Speaking & faculty fees$9,54124%
- Travel & lodging$8,00821%
- Food & beverage$8,24321%
- Education$490%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 17 | $10,473 |
| Lilly USA, LLC | 33 | $6,765 |
| Mannkind Corporation | 11 | $6,559 |
| Corcept Therapeutics | 24 | $3,769 |
| Abbott | 25 | $1,898 |
| Idorsia Pharmaceuticals US Inc | 1 | $1,520 |
| Sanofi | 1 | $1,496 |
| Novo Nordisk | 19 | $1,369 |
| AstraZeneca | 17 | $1,281 |
| Amgen(2 entities) | 21 | $666 |
| Johnson & Johnson | 10 | $473 |
| Cequr Corporation | 4 | $355 |
| Pfizer | 14 | $304 |
| Novartis | 8 | $268 |
| Insulet Corporation | 4 | $259 |
| Bayer | 6 | $259 |
| Sanofi-aventis U.S. LLC | 5 | $218 |
| Boehringer Ingelheim | 2 | $152 |
| AbbVie(2 entities) | 7 | $138 |
| Janssen Scientific Affairs, LLC | 1 | $123 |
| Tandem Diabetes Care, Inc. | 4 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $77 |
| Aimmune Therapeutics, Inc. | 1 | $77 |
| Lexicon Pharmaceuticals, Inc. | 3 | $71 |
| Lifescan, Inc. | 2 | $66 |
| Senseonics, Incorporated | 1 | $36 |
| Madrigal Pharmaceuticals | 2 | $36 |
| Dexcom, Inc. | 2 | $34 |
| Grifols USA, LLC | 2 | $33 |
| Boston Scientific | 2 | $32 |
| Nevro Corp. | 1 | $26 |
| Medtronic | 1 | $24 |
| Sequel Med Tech, LLC | 1 | $22 |
| GSK | 1 | $19 |
| Xeris Pharmaceuticals, Inc. | 1 | $18 |
| Ascensia Diabetes Care US Inc. | 1 | $16 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$39,060 in reported general payments places this provider in the 95th percentile of 1,221 family medicine providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 40 | $54,054 |
| OzempicSemaglutide | 56 | $53,218 |
| JardianceEmpagliflozin | 48 | $52,030 |
| RybelsusSemaglutide | 15 | $23,504 |
| EliquisApixaban | 13 | $10,714 |
| JanuviaSitagliptin Phosphate | 12 | $9,808 |
| Insulin Lispro | 13 | $1,272 |
| Rosuvastatin Calcium | 21 | $600 |
| Pioglitazone Hcl | 21 | $308 |
| Metformin Hcl | 16 | $284 |
| Atorvastatin Calcium | 12 | $241 |
| Bupropion Hcl SrBupropion Hcl | 15 | $170 |
| Metoprolol Succinate | 18 | $110 |
| Omeprazole | 23 | $107 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,369 | $76,72271 claims |
| Lilly USA, LLCMounjaro, Insulin Lispro | $6,765 | $55,32653 claims |
| Boehringer IngelheimJardiance | $152 | $52,03048 claims |
| PfizerEliquis | $304 | $10,71413 claims |
| MerckJanuvia | $12 | $9,80812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,221 family medicine providers in Oregon.
Other family medicine in Sisters
- Eden MillerBend$1.7M
- Anil RajaniHood River$325K
- Stephen NelsonMedford$101K
- Karen KahnAshland$86K
- Robert GobboPortland$53K
- Morris MaizelsCentral Point$25K
- Maureen MaysPortland$24K
- Nathaniel FondellMedford$21K
- Carl EricksonMilwaukie$14K
- Dana RhodeBend$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.